Literature DB >> 23786852

Perceived relapse risk and desire for medication assisted treatment among persons seeking inpatient opiate detoxification.

Genie L Bailey1, Debra S Herman, Michael D Stein.   

Abstract

Most patients with opioid addiction do not receive medication at the time of discharge from brief inpatient detoxification programs despite the high risk of relapse and the availability of three FDA-approved medications. We surveyed 164 inpatient opioid detoxification patients to assess desire for pharmacotherapy following detoxification program discharge. Participants were predominantly male (71.3%) and 80% had detoxed in the past. Reporting on their most recent previous inpatient detoxification, 27% had relapsed the day they were discharged, 65% within a month of discharge, and 90% within a year of discharge. 63% reported they wanted medication-assisted treatment (MAT) after discharge from the current admission. The odds of desiring a treatment medication increased by a factor of 1.02 for every 1% increase in perceived relapse risk (p<.01). These data suggest patient preference discussions including relapse risk could increase post-detox abstinence.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aftercare; Detoxification; Medication; Opiates; Relapse

Mesh:

Year:  2013        PMID: 23786852      PMCID: PMC4874241          DOI: 10.1016/j.jsat.2013.04.002

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  28 in total

Review 1.  Intramuscular extended-release naltrexone: current evidence.

Authors:  David R Gastfriend
Journal:  Ann N Y Acad Sci       Date:  2011-01       Impact factor: 5.691

2.  Assessing the service linkages of substance abuse agencies with mental health and primary care organizations.

Authors:  Shoou-Yih D Lee; Joseph P Morrissey; Kathleen C Thomas; W Craig Carter; Alan R Ellis
Journal:  Am J Drug Alcohol Abuse       Date:  2006       Impact factor: 3.829

3.  Multiple imputation by chained equations: what is it and how does it work?

Authors:  Melissa J Azur; Elizabeth A Stuart; Constantine Frangakis; Philip J Leaf
Journal:  Int J Methods Psychiatr Res       Date:  2011-03       Impact factor: 4.035

4.  Factors associated with frequent utilization of crisis substance use detoxification services.

Authors:  Emily Carrier; Jennifer McNeely; Iryna Lobach; Shane Tay; Marc N Gourevitch; Maria C Raven
Journal:  J Addict Dis       Date:  2011-04

5.  Evidence on the Chronic Care Model in the new millennium.

Authors:  Katie Coleman; Brian T Austin; Cindy Brach; Edward H Wagner
Journal:  Health Aff (Millwood)       Date:  2009 Jan-Feb       Impact factor: 6.301

6.  Pharmacotherapy in the treatment of addiction: methadone.

Authors:  Mary Jeanne Kreek; Lisa Borg; Elizabeth Ducat; Brenda Ray
Journal:  J Addict Dis       Date:  2010-04

7.  Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.

Authors:  Evgeny Krupitsky; Edward V Nunes; Walter Ling; Ari Illeperuma; David R Gastfriend; Bernard L Silverman
Journal:  Lancet       Date:  2011-04-30       Impact factor: 79.321

Review 8.  Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

Authors:  R P Mattick; J Kimber; C Breen; M Davoli
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

9.  Trends in inpatient detoxification services, 1992-1997.

Authors:  Tami L Mark; Joan D Dilonardo; Mady Chalk; Rosanna M Coffey
Journal:  J Subst Abuse Treat       Date:  2002-12

Review 10.  Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.

Authors:  Richard P Mattick; Courtney Breen; Jo Kimber; Marina Davoli
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08
View more
  30 in total

1.  Reasons for Benzodiazepine Use Among Persons Seeking Opioid Detoxification.

Authors:  Michael D Stein; Mitika Kanabar; Bradley J Anderson; Anna Lembke; Genie L Bailey
Journal:  J Subst Abuse Treat       Date:  2016-06-16

2.  Attitudes about medications for alcohol use disorder among individuals with serious mental illness: A health belief model analysis.

Authors:  Elizabeth Bromley; Derjung M Tarn; Michael McCreary; Brian Hurley; Allison J Ober; Katherine E Watkins
Journal:  J Subst Abuse Treat       Date:  2020-04-20

3.  Opioid-related US hospital discharges by type, 1993-2016.

Authors:  Cora Peterson; Likang Xu; Curtis Florence; Karin A Mack
Journal:  J Subst Abuse Treat       Date:  2019-05-10

4.  Attitudes toward opioid use disorder medications: Results from a U.S. national study of individuals who resolved a substance use problem.

Authors:  Brandon G Bergman; Robert D Ashford; John F Kelly
Journal:  Exp Clin Psychopharmacol       Date:  2019-09-26       Impact factor: 3.157

5.  Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.

Authors:  Kelly E Dunn; D Andrew Tompkins; George E Bigelow; Eric C Strain
Journal:  JAMA Psychiatry       Date:  2017-09-01       Impact factor: 21.596

6.  Trajectory classes of opioid use among individuals in a randomized controlled trial comparing extended-release naltrexone and buprenorphine-naloxone.

Authors:  Lesia M Ruglass; Jennifer Scodes; Martina Pavlicova; Aimee N C Campbell; Skye Fitzpatrick; Celestina Barbosa-Leiker; Kathleen Burlew; Shelly F Greenfield; John Rotrosen; Edward V Nunes
Journal:  Drug Alcohol Depend       Date:  2019-10-21       Impact factor: 4.492

7.  The relationship between treatment accessibility and preference amongst out-of-treatment individuals who engage in non-medical prescription opioid use.

Authors:  Andrew S Huhn; D Andrew Tompkins; Kelly E Dunn
Journal:  Drug Alcohol Depend       Date:  2017-09-09       Impact factor: 4.492

8.  NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.

Authors:  Joshua D Lee; Edward V Nunes; Patricia Novo Mpa; Genie L Bailey; Gregory S Brigham; Allan J Cohen; Marc Fishman; Walter Ling; Robert Lindblad; Dikla Shmueli-Blumberg; Don Stablein; Jeanine May; Dagmar Salazar; David Liu; John Rotrosen
Journal:  Contemp Clin Trials       Date:  2016-08-10       Impact factor: 2.226

9.  Association between mortality rates and medication and residential treatment after in-patient medically managed opioid withdrawal: a cohort analysis.

Authors:  Alexander Y Walley; Sara Lodi; Yijing Li; Dana Bernson; Hermik Babakhanlou-Chase; Thomas Land; Marc R Larochelle
Journal:  Addiction       Date:  2020-02-25       Impact factor: 6.526

10.  Preferences for Aftercare Among Persons Seeking Short-Term Opioid Detoxification.

Authors:  Michael D Stein; Bradley J Anderson; Genie L Bailey
Journal:  J Subst Abuse Treat       Date:  2015-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.